التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
CSL Ltd
Open
Sector
277.66 1.54
Overview
Share price change
24h
Min
273.65
Max
278.77
Income | 1.9B |
|---|---|
Sales | 8.1B |
P/E Sector Avg | 38.598 35.718 |
EPS | 4.159 |
Dividend yield | 1.319 |
Profit margin | 23.606 |
EBITDA | 1.7B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +21.34 upside |
Dividend yield Sector Avg | 1.32% 2.40% |
|---|---|
Next Earnings | ١١ فبراير ٢٠٢٥ |
Market Cap | -2.2B 134B |
|---|---|
Previous open | 276.12 |
Previous close | 277.66 |
News Sentiment
By Acuity
50%
50%
236 / 472 Ranking in Industrials
CSL Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CSL Ltd Forecast
Price Target
By TipRanks
21.34% upside
12 Months Forecast
Average 329.273 AUD 21.34%
High 348.5 AUD
Low 291.78 AUD
Based on 7 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.
Sentiment
By Acuity
236 / 472 Ranking in
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CSL Ltd
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.
